|
|
Article: Sucampo, BioVex Line Up To Take Shot At Public Markets.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Two firms cast their lines in the financial waters by filing for initial public offerings - Sucampo Pharmaceuticals Inc., which seeks up to $86.25 million, and BioVex Inc., which hopes to raise as much as $45 million.
Sucampo, of Bethesda, Md., did not specify the number of shares or the price per share.
In late January, the FDA approved the firm's selective chloride channel activator Amitiza (lubiprostone) capsules for chronic idiopathic constipation in adults. In pivotal trials, about 60 percent of patients who used the drug experienced a spontaneous bowel movement within the first 24 hours.
Partnered in the U.S. ...